State Drug Administration approves Gilead Xia Fanning ® to treat chronic hepatitis C virus infection in China

chronic hepatitis C is a major public health challenge worldwideIn China, nearly 10 million people are infected with hCV, of which about 58% are HCV-type 1 patientsrecently, Gilead Sciences (NASDAQ: GILD) announced that China's NationalDrug(http://Regulatory Authority has approved xia Fanning ® (Getty Paiway 90mg/Sophobuvir 400mg) for the treatment of adults and adolescents aged 12 to 18 with chronic hepatitis 1 virus (HCV) infection in Chinathe approval of Xia Fanning ®
Xia Fanning ® This approval is based on an open label phase 3b study conducted in 18 research centers in Chinese mainland from May 2016 to July 2017, assessing the effectiveness of® 12 weeks of treatment in 206 patients with gene type 1 hepatitis C in 206 cases of Gene 1 hepatitis C patients, including those without treatment and those without liver cirrhosis or with intricosised liver cirrhosisin the study, 100% of the enrolled patients achieved SVR12The most common adverse reactions in patients are viral upper respiratory tract infections and upper respiratory tract infections